Inquiry Basket
Loading ......
For decades, a single line on a laboratory report — "HBsAg positive" or "HBsAg negative" — was treated as the beginning and end of hepatitis B diagnosis. That simplicity is now obsolete. As the field shifts from mere suppression toward the more ambitious goal of a "functional cure," clinicians and researchers increasingly recognize that the surface antigen is necessary but insufficient. This article traces how hepatitis B diagnostics have evolved beyond HBsAg and what that means for management, surveillance, and the research reagents that make it possible.
The hepatitis B surface antigen tells you that the virus is present, but it tells you almost nothing about how actively it is replicating. A person can be HBsAg-positive with undetectable viral load on long-term therapy, or HBsAg-positive with millions of copies of HBV DNA circulating and aggressive liver inflammation. This is the core limitation: HBsAg is a marker of infection, not a direct readout of viral abundance or disease activity. For clinicians and patients interpreting an existing HBV-DNA result, the distinction is critical — the viral-load measurement, not the surface antigen, reveals whether the virus is being transcriptionally and numerically controlled.
That limitation shapes every downstream decision. Treatment initiation, the choice between watchful monitoring and antiviral therapy, and the assessment of transmission risk all depend on information HBsAg cannot provide alone. The modern diagnostic algorithm therefore pairs the surface antigen with nucleic-acid testing and additional serological markers.
Figure 1. Course of serum markers in acute resolving hepatitis B virus infection. (Source: Kramvis A, et al. 2022)
Where HBsAg shows presence, quantitative HBV DNA shows intensity. Nucleic-acid amplification and, increasingly, standardized international-unit reporting let clinicians track replication over time and confirm treatment response. A sustained drop in HBV DNA is the earliest and most reliable sign that nucleos(t)ide therapy is working; conversely, a rebound signals non-adherence or emerging resistance.
Hepatitis B e antigen, or HBeAg, adds another dimension. As a secreted core-protein derivative, HBeAg correlates with higher replication and greater infectivity, and its loss (with or without seroconversion to anti-HBe) has long been a treatment endpoint. Yet HBeAg status is imperfect — some patients remain HBeAg-negative but viremic, and some lose HBeAg yet never clear HBsAg. The triad of HBsAg, HBeAg, and quantitative HBV DNA thus forms the practical backbone of monitoring, and research-grade anti-HBe and anti-HBc antibodies alongside calibrated HBV DNA standards are the reference materials that make results comparable across settings.
Perhaps the most important reason not to stop at HBsAg is hepatitis D. The hepatitis delta virus is a defective agent that can only propagate inside an HBV-infected cell, borrowing the surface envelope that HBsAg provides. Consequently, HDV occurs exclusively in HBsAg-positive people, and it is the most severe form of viral hepatitis — accelerating fibrosis, raising the risk of cirrhosis, decompensation, and hepatocellular carcinoma far beyond HBV alone.
The diagnostic implication is direct: every HBsAg-positive person should, at least once, be screened for anti-HDV, with confirmation by HDV RNA where indicated. Historically this reflex testing was underused, leaving a sizable hidden population undiagnosed. Recent guidance now favors universal anti-HDV screening of all HBsAg-positive individuals, with HDV RNA quantification used to confirm active infection and monitor therapy. HDV forces the field to think in terms of two viruses sharing one surface antigen — a reminder that "HBsAg positive" can mask a very different prognosis.
First-line oral therapies — entecavir and the tenofovir formulations — are remarkably effective at suppressing HBV DNA and have a high genetic barrier to resistance. Yet resistance has not disappeared. In settings where prior exposure to lower-barrier agents occurred, multidrug-resistant variants can emerge, and even contemporary regimens demand vigilance. Close, regular HBV DNA monitoring is the safeguard: a rising viral load on therapy is the earliest clue to resistance, prompting genotypic testing and regimen adjustment before clinical breakthrough.
Large cohort studies of treated populations have mapped the prevalence and architecture of multidrug-resistance mutations, clarifying which patterns compromise both lamivudine-class and adefovir-class agents and how tenofovir-based combinations retain inhibitory power. These findings matter for surveillance because resistance is, fundamentally, an evolutionary signal detectable only through repeated quantitative testing. The reagents behind resistance surveillance — sequenced HBV standards, control panels, and validated immunoassay components — are quiet but essential infrastructure for long-term disease control.
Figure 2. Restoration of Antiviral Immunity in HBV. (Source: Thimme R, et al. 2013)
The most dynamic shift in hepatitis B thinking is the move from "control" to "cure." A functional cure is generally defined as sustained loss of HBsAg with undetectable HBV DNA, even if the viral genome persists quietly in the liver. Achieving it is hard: on current therapy, annual HBsAg loss occurs in only a small fraction of patients. But the payoff is large — HBsAg clearance dramatically lowers the risk of liver cancer and may allow safe discontinuation of lifelong medication.
This is why sensitive, quantitative HBsAg measurement has become a central research biomarker. Unlike a crude positive/negative strip, a quantitative HBsAg assay can track the slow decline of surface antigen during therapy, predict who is approaching seroclearance, and serve as a surrogate endpoint in cure trials. Reviews in the past two years have argued that high-sensitivity HBsAg loss may even approximate a "complete cure" signal, because the antigen originates from both the stable viral reservoir and integrated viral DNA. For the diagnostics community, this raises the bar: the next generation of reagents must detect HBsAg at far lower concentrations and distinguish free antigen, immune-complexed antigen, and mutant forms. Recombinant HBsAg preparations of defined purity, and research-grade anti-HBs antibodies with defined epitope specificity, are precisely the tools that let assay developers chase that sensitivity.
Behind every marker lies a human population. An estimated 250–300 million people live with chronic HBV, the majority undiagnosed, and hepatitis B accounts for the large majority of viral-hepatitis deaths. Yet the disease is marked as much by silence as by biology. Stigma and discrimination — lost employment, denied education, barred migration, and social isolation — are documented across dozens of countries and act as direct barriers to testing and care. Registries and qualitative studies alike show that fear of a positive HBsAg result can deter precisely the people who most need screening.
Addressing this is not peripheral to elimination; it is central. The same 2030 targets that call for 90% diagnosis cannot be met if a quarter-billion people avoid the clinic. Public-facing resources that explain an HBsAg-positive result in clear, non-judgmental language — emphasizing that chronic HBV is manageable, that vaccination protects the uninfected, and that everyday contact does not transmit the virus — are part of the intervention. A growing demand among adults for catch-up vaccination reflects both heightened risk awareness and the broadening of national prevention strategies; programs should meet that demand with the same evidence-based communication used elsewhere.
The future of hepatitis B diagnostics is increasingly multiplexed. Rather than running HBsAg, anti-HBs, HBeAg, and anti-HBc as separate single-plex assays, automated platforms can now measure several markers from one small sample, with quantitative output suitable for both screening and treatment monitoring. Proof-of-concept point-of-care work has demonstrated a portable, multiplexed serology panel capable of simultaneous HBsAg, HBeAg, and anti-HBs measurement, correlating well with established laboratory methods.
For researchers, multiplex serology is more than convenience. It enables population studies that capture the full serological landscape — who is susceptible, who is infected, who has recovered, who has been vaccinated — in a single workflow. The underlying reagents are generic but demanding: highly specific capture and detection antibodies, stable recombinant antigens, and rigorous standardization, the components that translate the biology of hepatitis B into data.
References
| Target | Cat. No. | Product Name | Species | Application | Detection Sample | |
| HBsAg | DEIA-NAB006 | NeutraEIA™ Human Anti-HBsAg Neutralizing antibodies Inhibitory Rate ELISA Kit | Human | Inhibition Rate | Serum or plasma (EDTA, citrate or heparin) | Inquiry |
| DEIA250602 | Monkey Anti-anti-HBsAg IgG ELISA kit | Monkey | Quantitative | Serum, Plasma | Inquiry | |
| DEIA250504 | Mouse anti-HBsAg IgM antibody quantitative ELISA kit | Mouse | Quantitative | Serum, plasma, or cell culture supernatants | Inquiry | |
| DEIASL271 | Rabbit Anti-HBsAg IgG ELISA Kit | Quantitative | Serum | Inquiry | ||
| DEIA-JY2436 | HBsAg Glycan ELISA Kit | Human | Quantitative | Cell culture supernatant, serum, and plasma | Inquiry | |
| DEIASL263-2 | Mouse Anti-HBsAg IgG ELISA Kit | Mouse | Quantitative | Serum | Inquiry | |
| DEIA-NS2502-4 | Hepatitis B Surface Antigen (HBsAg) ELISA Kit | HBV | Quantitative and qualitative | Cell culture, bioprocessing solutions, and or other samples (e.g., blood, saliva, mucosa) | Inquiry |
Loading ......
